In this online CME self-learning program:
Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. Myeloma is most common of the hematologic malignancies after non-Hodgkin lymphoma, with an incidence of a little over 32,000 and an annual mortality rate of just under 13,000. The peak incidence age of MM is at about 70 years of age, and the disease occurs twice as commonly in African Americans as it does in whites. Goals of care in MM are prolonging survival rates and improving quality of life, and treatment begins with induction and post-induction therapy, followed by hematopoietic stem cell transplant or maintenance therapy in patients ineligible for transplant. Relapse is indicated by any number of clinical signs, including hypercalcemia, renal insufficiency, anemia, new bone lesions or paraproteinemia.
This activity has been designed to update HCPs' knowledge around the current state of care in MM and improve their competence and performance in treating it.
The following healthcare professionals: Hematologists and oncologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other healthcare professional with an interest in or who clinically encounter patients with RRMM.
This program is supported by educational grants from Sanofi.
Learners may participate in this activity free of charge.
Release Date: May 27, 2021 -- Expiration Date: May 27, 2023
Faculty: Monique Hartley-Brown, MD
Faculty introduction, disclosures
Introduction content [Learning Objective #1]
Updates in treatment in patients with RRMM
· Evaluation of treatment response and surveillance
· RRMM goals of therapy
· Patient and disease-related factors driving therapeutic decision-making for RRMM [Learning Objective #1]
· Present and emerging pharmacotherapy and update in clinical trial evidence [Learning Objectives #2 & 3]
· First relapse
· Multiple relapse
· Treatment-emergent adverse effects and their management [Learning Objectives #2 & 3]
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCME Activity #201748769
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Monique A. Hartley-Brown, MD, MMSc., Assistant Professor of Medicine, Donald and Barbara Zucker School of Medicine, Hofstra University, has received financial compensation for consulting work from with Bristol Myers Squibb, GlaxoSmithKline, Sanofi, KaryoPharm, Guidepoint and Janssen.
Disclosures of Educational Planners: Charles Turck, PharmD, CEO of ScientiaCME, has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from Sanofi.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.